Vaccine advisory panel for the CDC set to meet Thursday and Friday to discuss who should get the updated boosters
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
WEDNESDAY, Aug. 31, 2022 (HealthDay News) -- The U.S. Food and Drug Administration on Wednesday gave the green light to updated COVID-19 booster shots from both Pfizer and Moderna that target omicron variants, paving the way for the shots to get into American arms within a few days.
"The FDA has been planning for the possibility that the composition of the COVID-19 vaccines would need to be modified to address circulating variants," Peter Marks, M.D., director of the FDA Center for Biologics Evaluation and Research, said in an agency news release announcing the emergency approval. "We sought input from our outside experts on the inclusion of an omicron component in COVID-19 boosters to provide better protection against COVID-19. We have worked closely with the vaccine manufacturers to ensure the development of these updated boosters was done safely and efficiently. The FDA has extensive experience with strain changes for annual influenza vaccines. We are confident in the evidence supporting these authorizations."
FDA Commissioner Robert Califf, M.D., urged Americans to get the new boosters. "As we head into fall and begin to spend more time indoors, we strongly encourage anyone who is eligible to consider receiving a booster dose with a bivalent [targets both the original virus and the omicron variants] COVID-19 vaccine to provide better protection against currently circulating variants," he said in the news release.
Now that the FDA has given its blessing, a vaccine advisory panel for the U.S. Centers for Disease Control and Prevention is set to meet Thursday and Friday to discuss who should get the updated boosters. Once the panel makes its recommendation, CDC Director Rochelle Walensky, M.D., is expected to sign off on those recommendations. The approvals will come before the possible emergence of a winter surge in COVID-19 cases.
The updated Moderna booster was authorized for those aged 18 years and older, while the Pfizer booster was approved for those 12 years and older, the FDA said. It should be given at least two months after primary vaccination or the original boosters.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Updated on September 21, 2022
Read this Next
Other Trending Articles